Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes (NCT05822609)
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes. The secondary objective is to determine the effects of semaglutide on change in kidney parameters (including kidney oxygenation and function) measured by MRI from baseline to 26 weeks in type 1 diabetes. Other objectives are to determine the glycemic effects and safety of semaglutide in type 1 diabetes.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Anschutz Medical Campus — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- University of Colorado Anschutz Medical Campus — Aurora, Colorado
- University of Washington — Seattle, Washington
- Providence Sacred Heart Medical Center — Spokane, Washington
- Toronto General Hospital, University Health Network — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (206) 685-1423
Email: ayerse@uw.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Diabetic Kidney Disease
- Decision Impact Trial of KidneyIntelX — Slingerlands, New York
- Prospective Decision Impact Trial of KidneyIntelX — Winston-Salem, North Carolina
- Pentoxifylline in Diabetic Kidney Disease — Phoenix, Arizona
- Prospective Decision Impact Clinical Utility Trial of KidneyIntelX — New York, New York
- Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients — San Francisco, California
- Role of Finerenone in African American Veterans With Diabetic Kidney Disease — Washington D.C., District of Columbia
Explore by condition: All Diabetic Kidney Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.